Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | TAMOXIFEN | authKW | 1287114 | 11% | 37% | 1654 |
2 | ESTROGEN RECEPTOR | authKW | 403295 | 8% | 17% | 1157 |
3 | AROMATASE INHIBITORS | authKW | 358680 | 3% | 42% | 416 |
4 | RALOXIFENE | authKW | 284683 | 2% | 38% | 359 |
5 | FULVESTRANT | authKW | 240194 | 1% | 67% | 173 |
6 | ENDOCRINE THERAPY | authKW | 192048 | 2% | 35% | 262 |
7 | GPR30 | authKW | 187538 | 1% | 66% | 136 |
8 | ANTIESTROGEN | authKW | 186089 | 1% | 39% | 227 |
9 | GPER | authKW | 185062 | 1% | 78% | 114 |
10 | BREAST CANCER | authKW | 184654 | 15% | 4% | 2289 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Oncology | 78703 | 38% | 1% | 5757 |
2 | Endocrinology & Metabolism | 35442 | 19% | 1% | 2932 |
3 | Obstetrics & Gynecology | 9249 | 8% | 0% | 1237 |
4 | Biochemistry & Molecular Biology | 4205 | 18% | 0% | 2694 |
5 | Cell Biology | 3049 | 9% | 0% | 1396 |
6 | Pharmacology & Pharmacy | 1401 | 8% | 0% | 1248 |
7 | Chemistry, Medicinal | 1309 | 4% | 0% | 534 |
8 | Reproductive Biology | 1159 | 2% | 0% | 312 |
9 | Medicine, Research & Experimental | 189 | 3% | 0% | 395 |
10 | Toxicology | 186 | 2% | 0% | 284 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | JC HEUSON CANCEROL MAMMAIRE | 28232 | 0% | 54% | 25 |
2 | RECEPTOR BIOL SECT | 27734 | 0% | 32% | 42 |
3 | BREAST | 24597 | 1% | 10% | 121 |
4 | HORMONAL CARCINOGENESIS | 22733 | 0% | 58% | 19 |
5 | NUCL RECEPTORS CELL SIGNALING | 22711 | 0% | 20% | 54 |
6 | TENOVUS CANC | 22695 | 0% | 29% | 38 |
7 | BREAST ONCOL PROGRAM | 19491 | 0% | 29% | 32 |
8 | LESTER SUE SMITH BREAST | 19223 | 0% | 17% | 54 |
9 | MIDLIFE HLTH | 17984 | 0% | 58% | 15 |
10 | TUMOR ENDOCRINOL | 17947 | 0% | 39% | 22 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | BREAST CANCER RESEARCH AND TREATMENT | 92311 | 4% | 8% | 577 |
2 | JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 66849 | 4% | 6% | 543 |
3 | MOLECULAR ENDOCRINOLOGY | 65667 | 3% | 8% | 423 |
4 | ENDOCRINE-RELATED CANCER | 19870 | 1% | 7% | 129 |
5 | BREAST | 19472 | 1% | 6% | 154 |
6 | STEROIDS | 15879 | 1% | 4% | 185 |
7 | BREAST CANCER RESEARCH | 14067 | 1% | 6% | 124 |
8 | CLINICAL BREAST CANCER | 13804 | 0% | 9% | 74 |
9 | MOLECULAR AND CELLULAR ENDOCRINOLOGY | 12399 | 2% | 3% | 233 |
10 | ENDOCRINOLOGY | 9866 | 2% | 1% | 354 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | TAMOXIFEN | 1287114 | 11% | 37% | 1654 | Search TAMOXIFEN | Search TAMOXIFEN |
2 | ESTROGEN RECEPTOR | 403295 | 8% | 17% | 1157 | Search ESTROGEN+RECEPTOR | Search ESTROGEN+RECEPTOR |
3 | AROMATASE INHIBITORS | 358680 | 3% | 42% | 416 | Search AROMATASE+INHIBITORS | Search AROMATASE+INHIBITORS |
4 | RALOXIFENE | 284683 | 2% | 38% | 359 | Search RALOXIFENE | Search RALOXIFENE |
5 | FULVESTRANT | 240194 | 1% | 67% | 173 | Search FULVESTRANT | Search FULVESTRANT |
6 | ENDOCRINE THERAPY | 192048 | 2% | 35% | 262 | Search ENDOCRINE+THERAPY | Search ENDOCRINE+THERAPY |
7 | GPR30 | 187538 | 1% | 66% | 136 | Search GPR30 | Search GPR30 |
8 | ANTIESTROGEN | 186089 | 1% | 39% | 227 | Search ANTIESTROGEN | Search ANTIESTROGEN |
9 | GPER | 185062 | 1% | 78% | 114 | Search GPER | Search GPER |
10 | BREAST CANCER | 184654 | 15% | 4% | 2289 | Search BREAST+CANCER | Search BREAST+CANCER |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 2 |